Immunotherapy Combo Offers Slight Survival Benefit in Melanoma [News in Brief]

Data on 2-year survival in the phase III CheckMate 067 trial testing nivolumab plus ipilimumab showed a slight survival benefit for the combination over nivolumab monotherapy—but the difference may not be dramatic enough to justify using the combination given the added side effects.

Source: Cancer Discovery - June 1, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research